Covered, compounding — a new, small payer. A 0.47% yield is small income, but it is covered about ten times over: $0.94 a quarter on a 9.3% payout. Regeneron only began paying a dividend in early 2025 — $0.88 to start, raised to $0.94 in January 2026 — and returns far more cash through buybacks (a 4.76% buyback yield per StockAnalysis) than through the dividend. Q2 2026 revenue grew 16.7% to $4.29 billion, so the payout has room to grow from here; it just has almost no track record yet.
Key risk: Product concentration — EYLEA and Dupixent still drive results, so biosimilar competition, pricing pressure, or a clinical setback in either franchise reaches earnings — and this young dividend — before the pipeline can replace it.
Changes if: the payout climbs toward 30% of earnings without the dividend growing, or the raise streak stalls at one. A second and third annual raise are the tripwire here.
- ✓Payout-coverage check: 9.3% of trailing earnings per MarketBeat (9.15% per StockAnalysis) — $3.76 indicated. Covered many times over; the constraint is history, not cash.
- ✓Yield check: 0.47% indicated — $0.94/qtr × 4 at the $805.02 close on Oct. 23, 2026. Real, earned yield for a single stock, not a special or a return of capital.
- !Dividend growth check: Only one increase so far: the dividend began at $0.88 in February 2025 and was raised to $0.94 in January 2026. A promising start, not a streak — the next two raises matter more than the first.
What this grade doesn't say: It screens the dividend only — covered, real, compounding. It says nothing about valuation or price: a well-covered payer can still be overpriced, and its price can still fall.